GRAL GRAIL, LLC
Company Analysis
Latest News
🔴 GRAIL is trading 10.13% down today amid reported profit-taking after roughly 85% one-month rally
GRAIL is trading at $121.74, down 10.13%, as coverage attributed pressure to profit-taking after a roughly 85% one-month rally. - No new GRAIL corporate...
🔴 GRAIL falls 4.3% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🔴 GRAIL is trading 4.3% down today amid rate concerns after hotter-than-expected inflation
GRAIL is trading 4.28% down at $133.57 as market concern that hotter-than-expected September inflation could keep interest rates higher weighs on shares. -...
🔴 GRAIL is trading 4.08% down in pre-market amid inflation-fueled rate concerns
GRAIL is trading 4.08% down at $134.00 in pre-market on October 15, with broader risk-off sentiment a possible backdrop; no new company-specific catalyst...
🔴 GRAIL is trading 4.3% down; cause remains unclear
GRAIL is trading 4.3% down at $134.51 on October 12; the specific reason for the decline remains unclear. - No reliable report identified a new...
🟢 GRAIL is trading 5% up with no clear catalyst identified
GRAIL is trading 5.17% higher at $139.47 on October 9, 2026, with no clear company-specific event identified to explain the move. - In pre-market, GRAIL was...
🟢 GRAIL, LLC is trading 8.68% up in pre-market
GRAL is trading at $144.12, up 8.68% in pre-market.
🔴 GRAIL is trading 4.2% down today amid macro and biotech-sector weakness
GRAIL is trading at $131.57, down 4.16%, amid broad market and biotech-sector weakness. - No clear negative company-specific catalyst has surfaced; the recent...
🔴 GRAIL is trading 10.25% down as the specific driver remains unclear
GRAIL is trading at $138.29, down 10.25%, with the specific driver of the October 6 decline unclear. - No reliable company-specific news was identified. GRAIL...
🔴 GRAIL is trading 4.3% down today
GRAIL is trading at $147.39 (-4.34%), with no reliable company-specific news found to explain the October 6 decline. - GRAIL announced new NHS-Galleri and...
🟢 GRAIL is trading 5% up today amid upcoming Galleri conference presentations
GRAIL is trading at $162.00, up 5.14%, as coverage links the rise to upcoming Galleri presentations and FDA review. - On October 5, GRAIL announced it will...
🟢 GRAIL is trading 5% up today after FDA panel endorsed Galleri’s potential benefits
GRAIL is trading at $150.47, up 5.03%, as optimism continues after an FDA advisory panel endorsed Galleri’s potential benefits. - The endorsement is a step...
🟢 GRAIL is trading 5% up today amid broader-market strength
GRAIL is trading at $139.40, up 5.16%, with broader-market strength providing context for the gain. - Major indices are also higher. - The weak September jobs...
🔴 GRAIL is trading 4.3% down today with no clear company-specific catalyst
GRAIL is trading 4.3% lower at $134.07 on October 1, 2026, with no new company-specific announcement clearly explaining the decline. - The latest major...
GRAIL Clears a Major FDA Hurdle for Its Cancer Blood Test — But Can the Stock Keep Climbing Without Insurance Coverage?
Shares of GRAIL surged to $150.24, extending a breathtaking +38% rally since September 22, after an FDA advisory panel gave a decisive thumbs-up to the...
🟢 GRAIL is trading 10% up today after FDA panel favored Galleri
GRAIL is trading at $150.24, up 10.01%, as gains extend after an FDA advisory panel voted in favor of Galleri, its multi-cancer detection test. - On September...
🟢 GRAIL is trading 4.12% up after FDA panel backed Galleri cancer test
GRAIL is trading up 4.12% at $142.19 on September 30, extending gains after the September 23 FDA advisory panel backed its Galleri cancer-detection test. - The...
🟢 GRAIL is trading 5% up today after Canaccord raised its target to $150
GRAIL is trading at $133.20, up 4.97%, after Canaccord Genuity raised its target to $150 from $80 and maintained a Buy rating on September 28. - The outlook...
🔴 GRAIL is trading 4.13% down today with no new company-specific catalyst identified
GRAIL is trading 4.13% down at $120.04, with no new company-specific catalyst identified for September 25, 2026. - On September 23, FDA advisers supported...
🟢 GRAIL is trading 10% up today after FDA panel supported Galleri’s benefit-risk profile
GRAIL is trading 10.21% up at $119.60 after an FDA advisory panel supported Galleri’s benefit-risk profile on September 23, 2026. - Advisers voted 7–2, with...